News

Argenx has entered into a definitive agreement to acquire Forte Biosciences in an all-cash transaction valued at approximately US$2.2 billion.

Bora Pharmaceuticals and Onconic Therapeutics have entered into a manufacturing agreement to support the U.S. clinical development of JAQBO, a potassium-competitive acid blocker (P-CAB)

Dassault Systèmes has signed a definitive agreement to acquire ArisGlobal in a deal valued at approximately US$1.8 billion in cash, with up to an additional US$200 million linked to multi-year AI-related revenue milestones.

Restore Vision has entered into a development and manufacturing partnership with Forge Biologics to support the advancement of RV-001, its investigational adeno-associated virus (AAV) gene therapy

Samsung Biologics has announced an all-cash public tender offer to acquire 100% of the share capital of PolyPeptide Group AG, a global contract development and manufacturing organisation (CDMO) specialising in peptide

Excalipoint Therapeutics has entered into a strategic partnership with DP Technology to co-develop a proprietary artificial intelligence (AI)-powered platform for the discovery of T-cell engagers (TCEs) and multi-specific antibodies.

Samsung Bioepis and Organon have expanded their Development and Commercialisation Agreement to introduce an additional biosimilar product in Australia through Organon ANZ.

Evonik has entered into a partnership with evitria to provide a ready-to-use transient protein expression kit based on Chinese Hamster Ovary (CHO) cells, helping biopharmaceutical researchers accelerate early-stage biologics development.

Pfizer and Astellas Pharma have received approval from the US Food and Drug Administration (FDA) for PADCEV (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab) or Keytruda

Teva Pharmaceuticals and Polpharma Biologics have entered into a global licensing agreement under which Teva will receive exclusive rights to commercialise both intravenous and subcutaneous formulations